[18F]-OC PET/CT与增强CT/MRI在神经内分泌肿瘤检测与评估中的比较
本回顾性研究纳入93例患者(45例疑似NEN用于诊断评估,48例病理确诊NEN用于检测转移或复发),共276个疑似NEN病灶,比较[18F]-OC PET/CT与增强CT/MRI的诊断效能。45例疑似患者中,[18F]-OC PET/CT诊断NEN的灵敏度96.3%、特异度77.8%、准确率88.9%,优于CT/MRI;276个病灶中灵敏度90.5%、特异度82.1%、准确率88.8%,均高于CT和MRI。
要点
- 45例疑似NEN患者中,[18F]-OC PET/CT诊断灵敏度96.3%、特异度77.8%、准确率88.9%,优于CT/MRI。
- 276个疑似NEN病灶中,[18F]-OC PET/CT诊断灵敏度90.5%、特异度82.1%、准确率88.8%,均高于CT和MRI。
- SUVmax、TBR、SUVhypophysis截断值分别为8.3、3.1、15.4时,鉴别NEN与非NEN病灶的灵敏度和特异度平衡最佳。
核心结论
- [18F]-OC PET/CT是用于NEN初始诊断及检测转移或术后复发的有前景的影像方法。
研究设计与样本
- 回顾性研究纳入93例接受[18F]-OC PET/CT及CT或MRI检查的患者,其中45例疑似NEN用于诊断评估,48例病理确诊NEN用于检测转移或复发。
- 共发现276个疑似NEN病灶,以组织病理学或影像学随访结果为最终诊断参考标准。
- [18F]-OC PET/CT图像采用视觉及半定量评估,测量肿瘤SUVmax、肿瘤/本底SUVmax比值(TBR)及垂体SUVmax(SUVhypophysis)。
主要发现
- 45例疑似NEN患者经切除或活检组织病理学确认,[18F]-OC PET/CT在G1-G3 NEN病灶中均显示高放射性摄取。
- 45例疑似患者中,[18F]-OC PET/CT诊断NEN的灵敏度96.3%、特异度77.8%、准确率88.9%,优于CT/MRI。
- 276个疑似NEN病灶中,[18F]-OC PET/CT诊断NEN的灵敏度90.5%、特异度82.1%、准确率88.8%,均高于CT和MRI。
- G1和G2 NEN的TBR高于G3,CT强化程度低于G3。
- G2中SUVmax和TBR与CT强化程度呈正相关,G1或G3中未见此相关性。
关键数值与推荐
- SUVmax、TBR、SUVhypophysis截断值分别为8.3、3.1、15.4时,[18F]-OC PET/CT鉴别NEN与非NEN病灶的灵敏度和特异度平衡最佳。
临床怎么用
- 原文结论认为[18F]-OC PET/CT是NEN初始诊断及检测转移或术后复发的有前景的影像方法。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Gallium-68 (68Ga)-labeled somatostatin analog (SSA) PET imaging has been widely used in clinical practice of neuroendocrine neoplasms (NENs). Compared with 68Ga, 18F has a great practical and economic advantage. Although a few studies have shown the characteristics of [18F] AlF-NOTA-octreotide ([18F]-OC) in healthy volunteers and small NEN patient groups, its clinical value needs further investigation. Herein, this retrospective study aimed to evaluate the diagnostic accuracy of [18F]-OC PET/CT in detecting NENs, as well as to compare it with contrast-enhanced CT/MRI. METHODS: We retrospectively reviewed the data of 93 patients who had undergone [18F]-OC PET/CT and CT or MRI scans. Of these patients, there were 45 patients with suspected NENs for diagnostic evaluation, and 48 patients with pathologically confirmed NENs for detecting metastasis or recurrence. [18F]-OC PET/CT images were evaluated visually and semi-quantitatively by measuring maximum standardized uptake value of tumor (SUVmax), tumor-to-background SUVmax ratio (TBR), and SUVmax of hypophysis (SUVhypophysis). A total of 276 suspected NEN lesions were found in these 93 patients. The results of histopathology or radiographic follow-up served as the reference standard for the final diagnosis. RESULTS: Forty-five patients with suspected NENs were confirmed by histopathological examination via resection or biopsy. [18F]-OC PET/CT showed high radiotracer uptake in the lesions of G1-G3 NENs. [18F]-OC PET/CT showed superior performance with 96.3% of sensitivity, 77.8% of specificity, and 88.9% of accuracy in diagnosing NENs compared to CT/MRI. When cutoffs of SUVmax, TBR, and SUVhypophysis were 8.3, 3.1, and 15.4, [18F]-OC PET/CT had the best equilibrium between sensitivity and specificity for differentiating NEN from non-NEN lesions. For a total of 276 suspected NEN lesions, the sensitivity, specificity, and accuracy of [18F]-OC PET/CT for diagnosis of NENs were 90.5%, 82.1%, and 88.8%, respectively, and were higher than those of CT and MRI. G1 and G2 NENs had higher TBR and lower CT enhancement intensity than G3. The SUVmax and TBR had a positive correlation with CT enhancement intensity in G2 rather than in G1 or G3. CONCLUSIONS: [18F]-OC PET/CT is a promising imaging modality for initial diagnosis and detecting metastasis or postoperative recurrence in NENs.
引用
- Chen D, Yang S, Chen J, et al. Comparison of [18F]-OC PET/CT and contrast-enhanced CT/MRI in the detection and evaluation of neuroendocrine neoplasms. Eur J Nucl Med Mol Imaging. 2023. PMID: 36971805. doi:10.1007/s00259-023-06200-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。